Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer

References

• Chevallier M, Borgeaud M, Addeo A, et al. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12(4):217–237. doi: 10.5306/wjco.v12.i4.217.
   PubMed Web of Science ®Google Scholar
• Ganti AK, Klein AB, Cotarla I, et al. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7(12):1824–1832. doi: 10.1001/jamaoncol.2021.4932.
   PubMed Web of Science ®Google Scholar
• Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13(1):58. doi: 10.1186/s13045-020-00881-7.
   PubMed Web of Science ®Google Scholar
• Vu P, Patel S. Non-small cell lung cancer targetable mutations: present and future. Precis Cancer Med. 2020;3:5–5. doi: 10.21037/pcm.2019.11.03.
   Google Scholar
• VanderLaan PA, Rangachari D, Majid A, et al. Tumor biomarker testing in non-small-cell lung cancer: a decade of change. Lung Cancer. 2018;116:90–95. doi: 10.1016/j.lungcan.2018.01.002.
   PubMed Web of Science ®Google Scholar
• Ricciut B, Wang C, Rizvi H, et al. Abstract 102: clinicopathological and molecular characteristics, treatment patterns, and outcomes in patients with KRAS p.G12C-mutated metastatic non-small cell lung cancer (NSCLC) in the AACR project GENIE database. Cancer Res. 2021;81(13_Supplement):102–102. doi: 10.1158/1538-7445.AM2021-102.
   Web of Science ®Google Scholar
• Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of American pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update. J Clin Oncol. 2018;36(9):911–919. doi: 10.1200/JCO.2017.76.7293.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. J Mol Diagn. 2018;20(2):129–159. doi: 10.1016/j.jmoldx.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531–542. doi: 10.1200/EDBK_237863.
   PubMedGoogle Scholar
• Raez LE, Brice K, Dumais K, et al. Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC). Clin Lung Cancer. 2023;24(2):120–129. doi: 10.1016/j.cllc.2022.11.007.
   PubMed Web of Science ®Google Scholar
• Lemmon CA, Zhou J, Hobbs B, et al. Modeling costs and life-years gained by population-Wide Next-Generation sequencing or single-gene testing in nonsquamous non-small-cell lung cancer in the United States. J Clin Oncol Precis Oncol. 2023;7:e2200294. doi: 10.1200/PO.22.00294.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Mutebi A, Zhou Z-Y, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small cell luncg cancer using a decision analytic model. J Clin Oncol Precis Oncol. 2019;3:1–9. doi: 10.1200/PO.18.00356.
   PubMed Web of Science ®Google Scholar
• Vanderpoel J, Stevens AL, Emond B, et al. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. J Med Econ. 2022;25(1):457–468. doi: 10.1080/13696998.2022.2053403.
   PubMed Web of Science ®Google Scholar
• Cheng MM, Palma JF, Scudder S, et al. The clinical and economic impact of inaccurate EGFR mutation tests in the treatment of metastatic non-small cell lung cancer. J Pers Med. 2017;7(3):5. doi: 10.3390/jpm7030005.
   PubMed Web of Science ®Google Scholar
• Mileham KF, Schenkel C, Bruinooge SS, et al. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: results of a survey of U.S. oncologists. Cancer Med. 2022;11(2):530–538. doi: 10.1002/cam4.4459.
   PubMed Web of Science ®Google Scholar
• Sheffield BS, Eaton K, Emond B, et al. Cost savings of expedited care with upfront Next-Generation sequencing testing versus single-gene testing among patients with metastatic non-small cell lung cancer based on current Canadian practices. Curr Oncol. 2023;30(2):2348–2365. doi: 10.3390/curroncol30020180.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Espirito JL, Chen L, et al. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US oncology network. Lung Cancer. 2022;166:197–204. doi: 10.1016/j.lungcan.2022.03.004.
   PubMed Web of Science ®Google Scholar
• Smith RE, Johnson ML, Gordan LN, et al. Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): an integra connect database (ICD) retrospective observational study. J Clin Oncol. 2022;40(16_suppl):1530–1530. doi: 10.1200/JCO.2022.40.16_suppl.1530.
   Web of Science ®Google Scholar
• Metro G, De Giglio A, Ricciuti B, et al. Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease. Drugs Context. 2022;11:1–10. doi: 10.7573/dic.2022-3-9.
   Google Scholar
• Centers for medicare & medicaid services. Physician Fee Schedule. Baltimore (MD): Centers for Medicare & Medicaid Services; 2022.
   Google Scholar
• Centers for medicare & medicaid services. Clinical Laboratory Fee Schedule. Baltimore (MD): Centers for Medicare & Medicaid Services; 2022.
   Google Scholar
• Gildea TR, DaCosta Byfield S, Hogarth DK, et al. A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. Clinicoecon Outcomes Res. 2017;9:261–269. doi: 10.2147/CEOR.S132259.
   PubMed Web of Science ®Google Scholar
• Sheehan DF, Criss SD, Chen Y, et al. Lung cancer costs by treatment strategy and phase of care among patients enrolled in medicare. Cancer Med. 2019;8(1):94–103. doi: 10.1002/cam4.1896.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. ASP Drug Pricing Files. Baltimore (MD): Centers for Medicare & Medicaid Services; 2022.
   Google Scholar
• Skinner KE, Fernandes AW, Walker MS, et al. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. J Med Econ. 2018;21(2):192–200. doi: 10.1080/13696998.2017.1389744.
   PubMed Web of Science ®Google Scholar
• Blumenthal G, Gong Y, Kehl K, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019;30(5):830–838. doi: 10.1093/annonc/mdz060.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi: 10.1056/NEJMoa1801005.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Consumer Price Index 2023 [cited 2023 April 21]. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm
   Google Scholar
• Brice K, Raez LE, Dumais K, et al. Liquid biopsies for the front line therapy decision in non-small cell lung cancer. J Clin Oncol. 2021;39(15_suppl):e21103–e21103. doi: 10.1200/JCO.2021.39.15_suppl.e21103.
   Web of Science ®Google Scholar
• Nesline MK, Knight T, Colman S, et al. Economic burden of checkpoint inhibitor immunotherapy for the treatment of non-small cell lung cancer in US clinical practice. Clin Ther. 2020;42(9):1682–1698 e7. doi: 10.1016/j.clinthera.2020.06.018.
   PubMed Web of Science ®Google Scholar
• Wong W, Sheinson D, Liu Y, et al. Costs associated with the use of multigene panel tests in three solid tumor types and the impact on insurance premiums. Future Oncol. 2023;19(10):705–714. doi: 10.2217/fon-2023-0094.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Maziak DE, Moore SM, et al. The need for speed in advanced non-small cell lung cancer: a population kinetics assessment. Cancer Med. 2021;10(24):9040–9046. doi: 10.1002/cam4.4411.
   PubMed Web of Science ®Google Scholar
• Sheinson D, Wong WB, Wu N, et al. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer. Lung Cancer. 2020;143:86–92. doi: 10.1016/j.lungcan.2020.03.005.
   PubMed Web of Science ®Google Scholar
• Goulart BHL, Chennupati S, Fedorenko CR, et al. Access to tyrosine kinase inhibitors and survival in patients with advanced EGFR(+) and ALK(+) positive non-small-cell lung cancer treated in the real-world. Clin Lung Cancer. 2021;22(5):e723–e733. doi: 10.1016/j.cllc.2021.01.019.
   PubMed Web of Science ®Google Scholar
• Levy BP, Nguyen D, Shih Y-H, et al. Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non–small-cell lung cancer (aNSCLC) in the United States. J Clin Oncol. 2023;41(16_suppl):9117–9117. doi: 10.1200/JCO.2023.41.16_suppl.9117.
   Web of Science ®Google Scholar
• Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585–4593. doi: 10.1158/1078-0432.CCR-15-3101.
   PubMed Web of Science ®Google Scholar
• Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-Mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018;13(8):1138–1145. doi: 10.1016/j.jtho.2018.03.035.
   PubMed Web of Science ®Google Scholar
• Scott JA, Lennerz J, Johnson ML, et al. Compromised outcomes in stage IV non-small-cell lung cancer with actionable mutations initially treated without tyrosine kinase inhibitors: a retrospective analysis of real-world data. J Clin Oncol Oncol Pract. 2023;20(1):145–153. doi: 10.1200/op.22.00611.
   PubMedGoogle Scholar
• Steuten L, Goulart B, Meropol NJ, et al. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. J Clin Oncol Clin Cancer Inform. 2019;3:1–10. doi: 10.1200/CCI.19.00002.
   PubMed Web of Science ®Google Scholar
• Vashistha V, Armstrong J, Winski D, et al. Barriers to prescribing targeted therapies for patients with NSCLC with highly actionable gene variants in the veterans affairs national precision oncology program. J Clin Oncol Oncol Pract. 2021;17(7):e1012–e1020. doi: 10.1200/OP.20.00703.
   PubMedGoogle Scholar
• U.S. Food & Drug Administration. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC 2021 [cited 2023 June 29]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc
   Google Scholar
• U.S. Food & Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer 2022 [cited 2023 June 29]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung
   Google Scholar
• U.S. Food & Drug Administration. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC 2022 [cited 2023 June 29]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc.
   Google Scholar
• Janssen Biotech, Inc. RYBREVANT® (amivantamab-vmjw) Highlights of Prescribing Information 2022 [cited 2023 May 30]. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.
   Google Scholar
• Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 Insertion-Mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391–3402. doi: 10.1200/JCO.21.00662.
   PubMed Web of Science ®Google Scholar
• Girard N, Park K, Tang K, et al. LBA5 amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): primary results from PAPILLON, a randomized phase III global study. Annal Oncol. 2023;34: s 1304. doi: 10.1016/j.annonc.2023.10.060.
   Web of Science ®Google Scholar
• Cho BC, Felip E, Spira AI, et al. LBA14 amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial. Annal Oncol. 2023;34: s 1306. doi: 10.1016/j.annonc.2023.10.062.
   Web of Science ®Google Scholar
• Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase 3 MARIPOSA-2 study. Annal Oncol. 2023;35:77–90. doi: 10.1016/j.annonc.2023.10.117.
   PubMedGoogle Scholar